NEWS HIGHLIGHTSMedia Articles Related to Qutenza (Capsaicin)
Erectile Dysfunction Tied To Long Term Painkiller Use
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2013.05.16]
A new study suggests that long term use of opioid prescription painkillers for back pain is tied to a higher risk of erectile dysfunction (ED). The findings are published in the 15 May online issue of the journal Spine. Lead author Richard A...
Painkillers Increase Risk of Erectile Dysfunction
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2013.05.15]
Regularly taking prescription painkillers, commonly called opioids, is linked to a greater risk of erectile dysfunction (ED) in men, according to a new study published in Spine. Over 11,000 men suffering from back pain were involved in the research...
Retooling Pain Assessment for Older Adults
Source: Medscape Emergency Medicine Headlines [2013.05.14]
Current pain assessment tools for older adults are inadequate, and education for healthcare professionals falls short in meeting the unique challenges posed by pain management for elderly patients.
Medscape Medical News
Tanezumab Makes Good in Chronic Back Pain (CME/CE)
Source: MedPage Today Neurology [2013.05.14]
NEW ORLEANS (MedPage Today) -- The controversial agent tanezumab, which was once put on an FDA regulatory hold, offered durable reduction of chronic low back pain, a long-term safety and efficacy study showed.
Persistent Pain After Sexual Assault Often Untreated
Source: Medscape Nurses Headlines [2013.05.13]
Although pain is common after sexual assault, more than 50% of women don't seek appropriate medical care 6 weeks after presenting to the ED.
Medscape Medical News
Published Studies Related to Qutenza (Capsaicin)
Topical capsaicin (low concentration) for chronic neuropathic pain in adults. [2012]
CONCLUSIONS: There were insufficient data to draw any conclusions about
Capsaicin instillation for postoperative pain following total knee arthroplasty: a preliminary report of a randomized, double-blind, parallel-group, placebo-controlled, multicentre trial. [2011.12.01]
BACKGROUND: Pain following total knee arthroplasty (TKA) interferes with rehabilitation. Capsaicin applied in high concentration to nociceptors can cause relatively selective C-fibre desensitization for a period of weeks to months. Resultant long-lasting analgesia might facilitate rehabilitation. OBJECTIVE: The objective of this study was to determine if direct instillation of a high-concentration capsaicin preparation into the wound following TKA would provide pain relief, improve physical functioning and rehabilitation, and reduce opioid requirements... CONCLUSION: Despite having higher BMIs, patients in the capsaicin group achieved comparable or better pain scores with significantly less opioid use in the first 3 postoperative days. They also had less pruritus, which may have been a consequence of the opioid-sparing effect. The effects of capsaicin with respect to function, however, appeared to be longer lasting, with improved active ROM reported at 14 days.
A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis. [2011.08]
OBJECTIVE: To investigate the efficacy and safety of ICX72 or Sinus Buster, a proprietary homeopathic preparation of Capsicum annum and Eucalyptol, versus placebo administered continuously over 2 weeks in subjects with a significant component of nonallergic rhinitis (NAR)... CONCLUSION: This is the first controlled trial demonstrating intranasal capsaicin, when used continuously over 2 weeks, rapidly and safely improves symptoms in rhinitis subjects with a significant NAR component. Copyright (c) 2011 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Self-reported sleep duration associated with distraction analgesia, hyperemia, and secondary hyperalgesia in the heat-capsaicin nociceptive model. [2011.07]
Although sleep deprivation is known to heighten pain sensitivity, the mechanisms by which sleep modifies nociception are largely unknown. Few studies of sleep-pain interactions have utilized quantitative sensory testing models that implicate specific underlying physiologic mechanisms...
Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial. [2011.03]
This study evaluated the effects of topical lidocaine on skin sensation and on intradermal capsaicin-induced pain and hyperalgesia. A randomized, double-blinded, placebo controlled methodology was used...
Clinical Trials Related to Qutenza (Capsaicin)
The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain [Recruiting]
Subcutaneous treprostinil (Remodulin) is effective therapy for pulmonary arterial
hypertension, a life threatening disease of the lung blood vessels. Unfortunately,
treprostinil is irritating to the skin and many patients experience intense pain at the
infusion site for the first 7-10 days after placing a new subcutaneous infusion site.
Qutenza is an FDA approved formulation of 8% capsaicin that is approved for the treatment of
post-herpetic neuralgia, a painful skin condition. The investigators hypothesize that
pretreatment of an area of skin with Qutenza would decrease the pain associated with a new
treprostinil infusion site. The investigators hope that Qutenza will decrease both the
intensity of the pain and the duration of the pain after patients place a new treprostinil
infusion site.
In this initial study, the investigators will provide Qutenza in open-label, unblinded
fashion and ask patients to rate their pain using a diary tool with which they are already
comfortable.
Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch [Recruiting]
The Summary of product characteristics (SmPC) for QUTENZA advises that topical anaesthetic
is applied prior to the application of QUTENZA. This is a multi-center, randomized,
assessor-blinded study which will investigate the use of an oral analgesic as an alternative
form of pre-treatment for QUTENZA.
Acute Response Capsaicin Flare Study [Recruiting]
Prior to administering PF-04427429 to patients we wish to increase the understanding of
functional effects associated with calcitonin gene related peptide (CGRP) pathways. This
study will examine whether it is possible for a single dose of PF-04427429 to acutely
attenuate a capsaicin induced flare response.
Safety and Effectiveness of Repeated Administration of QUTENZA Patches for Treatment of Pain Caused by Nerve Damage [Recruiting]
In this study all patients will be treated with the same medicine, the QUTENZA patch.
Subjects will receive up to 6 QUTENZA patch applications over 12 months.
Qutenza®-Remodulin® in Pulmonary Arterial Hypertension Patients [Recruiting]
The investigators hypothesise that pre-application of Qutenza® patches to the skin may
reduce pain at the site of Remodulin® SC infusion (sited 1 to 2 weeks later at the site of
Qutenza pre-application), in which case it would greatly improve the quality of life of the
patients, and enable many more to continue with this treatment. It may also provide new
information to support the use of Qutenza® patches for preventing and reducing pain produced
by inflammation.
The present study will explore the efficacy of single applications of Qutenza® (capsaicin 8%
patch) in reducing site pain caused by continuous SC infusion of Remodulin®, in pulmonary
arterial hypertension patients, as assessed by changes in subjective pain rating score
and/or pain and sensory testing.
Reports of Suspected Qutenza (Capsaicin) Side Effects
Application Site Pain (26),
Application Site Erythema (15),
Condition Aggravated (8),
Hypertension (7),
Neuralgia (7),
Pain (6),
Application Site Swelling (5),
Application Site Pruritus (5),
Dizziness (5),
Application Site Vesicles (5), more >>
|
